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Breast cancer prognosis <p>A feature selection method was used in an analysis of three major microarray expression datasets to identify molecular subclasses and  prognostic markers in estrogen receptor-negative breast cancer, showing that it is a heterogeneous disease with at least four main sub- types.</p>
Abstract
Background: Estrogen receptor (ER)-negative breast cancer specimens are predominantly of high
grade, have frequent p53 mutations, and are broadly divided into HER2-positive and basal subtypes.
Although ER-negative disease has overall worse prognosis than does ER-positive breast cancer, not
all ER-negative breast cancer patients have poor clinical outcome. Reliable identification of ER-
negative tumors that have a good prognosis is not yet possible.
Results: We apply a recently proposed feature selection method in an integrative analysis of three
major microarray expression datasets to identify molecular subclasses and prognostic markers in
ER-negative breast cancer. We find a subclass of basal tumors, characterized by over-expression of
immune response genes, which has a better prognosis than the rest of ER-negative breast cancers.
Moreover, we show that, in contrast to ER-positive tumours, the majority of prognostic markers
in ER-negative breast cancer are over-expressed in the good prognosis group and are associated
with activation of complement and immune response pathways. Specifically, we identify an immune
response related seven-gene module and show that downregulation of this module confers greater
risk for distant metastasis (hazard ratio 2.02, 95% confidence interval 1.2-3.4; P  = 0.009),
independent of lymph node status and lymphocytic infiltration. Furthermore, we validate the
immune response module using two additional independent datasets.
Conclusion: We show that ER-negative basal breast cancer is a heterogeneous disease with at
least four main subtypes. Furthermore, we show that the heterogeneity in clinical outcome of ER-
negative breast cancer is related to the variability in expression levels of complement and immune
response pathway genes, independent of lymphocytic infiltration.
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Background
It is widely recognized that estrogen receptor (ER)-positive
(ER+) and ER-negative (ER-) breast cancers are two different
disease entities. Generally, ER- tumours tend to be of high
grade, are more frequently p53 mutated, and have worse
prognosis compared with ER+ disease. Moreover, while ER+
disease can be treated with hormone therapy, the only tar-
geted therapy available for ER- patients is a monoclonal anti-
body that binds to the ERBB2 receptor and that is effective
only for those ER- tumours with HER2/ERBB2 over-expres-
sion.
In spite of these clinical advances, ER+ and ER- breast cancers
remain heterogeneous diseases, and little is known regarding
why patients with the same histopathologic characteristics
may have widely different clinical outcomes [1]. This is partic-
ularly true for the basal subtype of ER- breast cancer, which is
commonly defined by over-expression of cytokeratin markers
(CK 5/6 and CK 14) and which is often also HER2 negative
(HER2-) [2]. Most recent efforts to obtain a molecular under-
standing of the observed heterogeneity have focused on ER+
breast cancer, where gene expression signatures that are
either prognostic or predictive of response to hormone ther-
apy have been derived [3-10]. In contrast, few studies have
thus far attempted to derive a prognostic signature within ER-
breast cancer. Although cytokeratin markers have been
shown to correlate with poor prognosis in breast cancer [11-
14], an attempt to correlate basal markers with survival
within ER- disease has shown that these markers were not
predictive of outcome [15]. Based on our work presented
here, it appears that the prognostic 'signal' in ER- breast can-
cer is much weaker than that in ER+ disease. This precludes
the use of traditional supervised approaches, which assume a
sufficiently low false discovery rate (FDR) for deriving gene
expression based classifiers. A similar observation was
reported by others [16].
Recently, we proposed a novel feature selection method (Pro-
file Analysis using Clustering and Kurtosis [PACK]) [17], that
selects genes using a pattern recognition method and that
may significantly reduce the FDR. Using PACK in an inte-
grated cohort of 186 ER- samples and 1,200 genes, we were
able to identify distinct molecular subtypes, including a good
prognosis subclass characterized by over-expression of
immune response genes. However, these results were not val-
idated in external cohorts.
The purpose of this work is to extend our preliminary findings
[17] by applying PACK to the same three breast cancer data-
sets [5,9,18], but now using a much larger set of common
genes (we rescued a significantly larger number of genes from
our study [9] by imputing missing data, which led to a much
larger number of overlapping genes, approximately 5,000,
with the other two arrays.), and to further validate our find-
ings using two external independent cohorts [7,19]. More
generally, our goal is to elucidate the molecular taxonomy of
ER- breast cancer and, if possible, to find different prognostic
subclasses and the corresponding prognostic markers.
Results
The FDR is higher in ER- breast cancer
To understand why in ER- breast cancer it has not been possi-
ble to derive a validated prognostic signature using conven-
tional approaches, we compared the FDR for ER+ and ER-
disease. We used as cohorts integrated datasets obtained by
merging together three of the largest profiled breast cancer
cohorts [5,9,18] using the z-score transformation, a proce-
dure that we validated previously [17]. Briefly, the z-score
transformation shifts the mean of each gene expression vec-
tor in each cohort to zero, while scaling its variance to unity.
The transformed gene expression vectors are then merged
across cohorts. This merging step resulted in integrated
expression matrices of 186 ER- and 527 ER+ tumors profiled
over a common set of 5,007 genes. To enable the comparison,
we selected at random 186 ER+ tumors from the 527 available.
We then used the univariate Cox proportional hazards model
with time to distant metastasis (TTDM) and overall survival
as end-points to obtain P values of significance for all the
genes. Next, we estimated, for each choice of significance
threshold, the number of false positives using the q-value
approximation [20]. The numbers of significant genes and
false positives as a function of the significance threshold were
then plotted for ER+ and ER- breast cancer and for the two dif-
ferent end-points used (Figure 1). We verified that the curves
for ER+ breast cancer were robust to random selections of the
186 ER+ tumors. This showed that the FDR is much higher in
ER- tumours and motivated us to develop a different feature
selection approach based on a pattern recognition algorithm
(PACK) [17].
Finding ER- subclasses using PACK
If the aim is to identify subclasses within a tumor type, then it
is natural that unsupervised methods be applied to sample
sets that are composed entirely of this tumor type. In fact,
given the hierarchical ER+/ER- subdivision for breast cancer,
it is questionable whether ER- subgroups can be correctly
defined based on clusters that were derived by using both ER+
and ER- samples, as was done in other studies (for example
[21-23]). To see this, assume that all tumor types and genes
are used in the clustering algorithm. It is very likely that the
clusters within ER- tumors reflect not only the interesting var-
iability of genes within ER- tumors but also the variability of
genes that are important for classification of ER+ tumors. The
variability of these genes in ER- tumors may represent unde-
sired noise, which, if not removed, can affect the inferred
clusters. Thus, in order to identify relevant subtypes of ER-
tumors more robustly, we decided to use ER- tumors only.
Moreover, in view of the relatively high FDR in ER- disease,
we decided to apply the PACK methodology, which has
already been shown to provide a more reliable identification
of molecular classifiers [17]. Because PACK requires largehttp://genomebiology.com/2007/8/8/R157 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. R157.3
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sample sizes (for small sample sizes, kurtosis estimates can
have large variance and clustering algorithms that aim to pre-
dict the optimal number of clusters have a high false negative
rate), we applied it to the integrated data matrix derived pre-
viously. Two additional independent ER- cohorts [7,19] were
left out to serve as validation studies. The five microarray
datasets used are summarized in Table 1 by platform type,
number of ER- samples, and number of poor outcome events.
Briefly, we review the concepts that underpin PACK (see
Materials and methods, below, and Figure 2). The hypothesis
is that genes that play an important role as classifiers or
biomarkers are more likely to have expression profiles that
are mixtures of gaussian distributions. On the other hand,
false positives, in spite of their spurious association with a
phenotype, are less likely to be described by a mixture of dis-
tributions. Thus, selecting genes based on whether they have
structure in their expression profiles is likely to pick out the
relevant markers from those that are just false positives. Next,
we propose to focus on those genes that define the largest
subgroups. Although genes that define small subgroups are
also of interest, it is natural to identify first those genes that
define the largest subclasses. While such features can be
found from the inferred cluster sizes, it turns out that such
features are generally also characterized by a negative (or
close to zero) kurtosis profile (see Materials and methods,
below) [17]. As shown previously, negative kurtosis expres-
sion profiles are in effect a mixture of at least two (gaussian)
distributions of approximately equal weights. Thus, by select-
ing those genes that have the most negative kurtosis expres-
sion profiles, we have identified the markers that define the
largest subclasses within the sample set (Figure 2). It is clear
that many of these features will be highly correlated because
they define almost the same subclasses. It follows that further
application of traditional clustering algorithms over these
negative kurtosis profiles will enable reliable identification of
the major subclasses within the sample set. We note that
because we are interested in the most negative kurtosis pro-
files and because the clusters in the individual gene profiles
are only needed to study the cluster distribution of pheno-
types, the cluster inference step on the individual gene pro-
files (known as PAC) can be performed after computation of
kurtosis (known as PAK) on the selected subset of negative
kurtosis profiles (Figure 2).
FDR comparison in ER- and ER+ breast cancer Figure 1
FDR comparison in ER- and ER+ breast cancer. For various significance 
thresholds (sigth), we plot the fraction of observed genes with P values 
less than the significance threshold (black) as well as the corresponding 
fraction of false positives, as estimated using a q value analysis (red). (a) 
Overall survival for ER+ breast cancer. (b) Overall survival for ER- breast 
cancer. (c) Time to distant metastasis for ER+ breast cancer. (d) Time to 
distant metastasis for ER- breast cancer. P values were obtained from the 
log-rank test using Cox regression models. ER, estrogen receptor; FDR, 
false discovery rate.
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Table 1
Breast cancer datasets used
Ref. Cohort name Oligo microarray platform ER- ER+
n Death/distant
metastasis (n)
n Death/distant
metastasis (n)
[18] NKI2 Agilent 69 34 226 45
[5] EMC Affymetrix 77 27 208 80
[9] NCH Agilent 40 14 93 21
[19] UPP Affymetrix 34 6 213 49
[7] JRH-2 Affymetrix 24 6 72 17
ER, estrogen receptor.R157.4 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. http://genomebiology.com/2007/8/8/R157
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Distinct molecular subgroups of ER- breast cancer
Applying PAK to the integrated ER- data matrix of 5,007
genes, we found 813 genes with a negative kurtosis profile
(Additional data file 1). Interestingly, applying the same anal-
ysis to ER+ breast cancer, we found only a much smaller
number (193) of negative kurtosis profiles (Additional data
file 2), despite there being roughly twice as many bimodal
profiles in ER+ breast cancer (about 4500 in ER+ versus about
2,500 in ER-). We verified by explicit simulation that the sig-
nificantly lower proportion of negative kurtosis profiles in
ER+ disease could not be explained by the larger sample size
in ER+  (527) compared with ER-  disease (186; data not
shown).
Having identified the relevant features, we next clustered the
ER- tumors over these. Using hierarchical clustering with
Pearson correlation metric and complete linkage, we found
that samples clustered into five main groups, each character-
ized by the expression patterns of four gene clusters that were
found to be strongly enriched for specific gene ontologies
(Figure 3a and Additional data file 3). One group was charac-
terized by over-expression of ERBB2, the steroid hormone
receptor AR, and genes related to steroid estrogen response
(such as GATA3, TFF1, and DNALI1). This subtype is there-
fore similar to the apocrine subclass, recently proposed
[24,25], which is characterized by over-expression of AR and
genes that are either direct targets of ER or responsive to
estrogen [24,25]. Thus, we decided to call this ER- subtype
(over-expressing steroid response genes) 'SR+', although it is
clear that it also defines the well known HER2+ subtype.
The other four groups were characterized mainly by absent or
lower expression of these steroid response genes. One of these
four clusters was characterized by over-expression of genes
related to cell cycle and cell proliferation pathways (CC+), and
another cluster also had over-expression of immune response
PACK flowchart Figure 2
PACK flowchart. (a) A schematic diagram of PACK, as used in this study. For each gene expression profile an unbiased estimate of its kurtosis, K, is 
computed. Genes with negative kurtosis are selected because only these define large subgroups (of sizes >22% of the total sample size). Further 
unsupervised clustering may then be performed on this subset of negative kurtosis profiles to find novel tumor subclasses. Alternatively, to find robust 
prognostic markers, negative kurtosis profiles are filtered further based on whether there is evidence of bimodality (C = 2). This step requires a cluster 
inference algorithm and a model selection criterion to discard those profiles that are best described by a single gaussian (C = 1; by random chance gaussian 
profiles may have negative kurtosis). Correlation to phenotypes (here phenotypes) is done with Fisher's test to evaluate whether the distribution of the 
categorical phenotype across the two clusters is significantly different from random. (b) Density curves of typical bimodal negative and positive kurtosis 
gene expression profiles. X-axis shows gene expression on a log2 scale. PACK, Profile Analysis using Clustering and Kurtosis.
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genes (CC+/IR+). For the remaining two clusters, one was
characterized by over-expression of extracellular matrix
genes (ECM+), and the other was characterized by over-
expression of immune response genes (IR+) only.
Relation to the intrinsic subtype classification
In order to relate the five identified molecular subtypes to the
intrinsic breast cancer classification [21,26], we used the
recently validated single sample predictor (SSP) [23] to clas-
sify the 186 ER- samples into the various intrinsic subtypes
(Figure 3a and Table 2). In addition, we studied the expres-
sion profiles of recently validated basal markers [27] and
genes in the ERBB2 amplicon across the five identified clus-
ters (Figure 3a and Additional data file 4). Based on these fig-
ures and Table 2, we could draw the following conclusions.
First, the SR+ cluster was highly correlated with the usual
HER2+ intrinsic subtype. Second, the CC+/IR+ and CC+ clus-
ters defined distinct subtypes of basal tumors. Third, the
ECM+ cluster was mostly basal, but it contained a relatively
high proportion of normal-like and luminal-A-like ER-
tumors; it also exhibited the most varied grade distribution,
with most low-grade ER-  tumors falling into this class.
Finally, the main constituents of the IR+ cluster were basal
and HER2+.
It further follows from these observations that ER- normal
and luminal A samples were predominantly characterized by
over-expression of ECM genes. ER- basal tumors, on the other
hand, exhibited a more complex pattern and appeared to
divide into at least four subgroups (CC+/IR+, CC+, ECM+, and
IR+).
To investigate further the relation of our five ER- subclasses
with the intrinsic subtypes, we considered to which ER- sub-
class ER+ samples of known intrinsic subtype were most sim-
ilar. To this end we first constructed, for each of the five ER-
subclasses, mean centroids over the 813 negative kurtosis
genes (Additional data file 5). To validate the centroids, the
same ER- samples were assigned a subclass using a nearest
centroid criterion (samples for which the largest Pearson cor-
relation coefficient was <0.25 were considered unclassified;
see Materials and methods, below), which showed that 156
(84%) were classified, of which 143 (92%) were assigned the
correct subclass. Next, using the SSP to classify the 527 ER+
samples into the intrinsic subtypes, we then assigned each of
the 527 ER+ samples into an ER- subclass based on the same
nearest centroid criterion (Table 3). As expected, only 4% of
ER+ tumors were classified as basal, whereas the majority
(82%) of them were luminal. Moreover, the analysis showed
that ER+ luminal B samples were most similar to CC+ and
CC+/IR+ ER- samples, which is consistent with the fact that all
of these samples over-express cell cycle and cell proliferation
genes. In contrast, ER+ luminal A samples were most similar
to ECM+ (63%), IR+ (26%), and SR+ (8%) ER- samples. Not
surprisingly, almost all (16/19 [84%]) 'normal' ER+ samples
were most similar to ECM+ ER- samples. All basal ER+ sam-
ples had expression profiles most similar to CC+/IR+ and CC+
subtypes. Interestingly, only 16 of the 42 (38%) ER+ HER2+
tumors exhibited significantly correlated expression profiles
to any one of the five ER- subclasses, with most of these (11)
mapping to the CC+/IR+ subtype.
A subgroup of good prognosis in ER- breast cancer
We next considered whether the five identified clusters were
associated with different prognostic groups. Because we had
merged different cohorts, and it is questionable whether sur-
vival data can be also merged together, we decided to test first
the clusters for association with clinical outcome by using a
dichotomized outcome variable. Specifically, poor outcome
was defined as any death or distant metastasis event, whereas
good outcome was defined as a patient alive or with no distant
metastasis. By studying the distribution of good and poor out-
come events in the respective clusters, significant associa-
tions with prognosis could be found by means of Fisher's
exact test (Table 2). Interestingly, this showed that the IR+
subgroup had better prognosis when compared with the
ECM+ (P  = 0.08), CC+ (P  = 0.03), and SR+ (P  = 0.005)
subclasses.
Compared with the CC+/IR+ subgroup it also had better prog-
nosis, although the difference was not statistically significant
(P = 0.19). We thus combined the CC+/IR+ and IR+ subclasses
together and evaluated the prognosis of this larger subclass
relative to the rest of ER-  samples. Consistent with our
previous result [17] we found that the ER-  tumors over-
expressing immune response genes had better prognosis than
ER- samples that did not (P = 0.02).
To further confirm our findings, we also generated Kaplan-
Meier survival curves for the five identified subclasses using
TTDM as the end-point (Figure 3b). This showed that the SR+
and CC+ subclasses had worst prognosis, whereas the IR+ sub-
class was the group with best prognosis. Specifically, relative
to the IR+ subclass the SR+ subgroup had a hazard ratio (HR)
of 3.70 (95% confidence interval [CI] 1.49 to 9.24; P = 0.005),
whereas the CC+ subgroup had an HR of 2.75 (95% CI 1.07 to
7.05; P = 0.035). Similarly, relative to the CC+/IR+ subclass,
the SR+ subgroup had an HR of 2.35 (95% CI 1.13 to 4.88;
P = 0.02), whereas for the CC+ subgroup it did not quite reach
statistical significance (HR 1.80, 95% CI 0.83 to 3.89;
P = 0.13). We verified the statistical significance of these sur-
vival differences by 10,000 random permutations of the sam-
ples, which showed that the theoretical P  value estimates
above were essentially identical to the empirically derived P
values.
Prognostic markers in ER- tumors are associated with 
immune response functions
The better prognosis of the IR+ subclass is likely due to spe-
cific genes that are individually prognostic. In order to find
these, we applied the PAC algorithm to the 813 genes with
negative kurtosis expression profiles. Briefly, this procedureR157.6 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. http://genomebiology.com/2007/8/8/R157
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Figure 3 (see legend on next page)
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selects features based on whether their expression profiles
are best described as a mixture of gaussians or not, and then
evaluates whether the distribution of good and poor outcome
events among the inferred clusters is statistically different
from random or not. Applying PAC, we found 22 genes with a
Fisher test P < 0.05 (Additional data file 1). A Gene Ontology
(GO) enrichment analysis of these 22 genes using the GOTree
Machine [28] showed that immune/defense response was the
most enriched GO, with seven genes falling into this category
(C1QA, IGLC2, LY9, TNFRSF17, SPP1, XCL2, and HLA-F).
The expression profiles for these seven genes confirmed the
presence of distinct clusters with nonrandom distributions of
good and poor outcome samples (Figure 4 provides detailed
profiles of C1QA and IGLC2).
Molecular subclasses in ER- breast cancer Figure 3 (see previous page)
Molecular subclasses in ER- breast cancer. (a) Complete linkage hierarchical clustering of 186 ER- breast tumors over 813 genes with negative kurtosis 
profiles. Five sample clusters were identified and characterized in terms of the patterns of over-expression and under-expression of four gene clusters 
related to cell cycle (CC; blue), immune response (IR; red), extracellular matrix (ECM; green), and steroid hormone response (SR; pink) functions. Panels 
show the distribution of the SSP subtype [23], the lymphocytic infiltration score, histologic grade, basal marker [27], and ERBB2+ amplifier subtype. Panel 
color codes: SSP (pink = HER2, brown = basal, dark green = normal, sky blue = luminal A, and blue = luminal B); LYM.INF (black = high, gray = low, and 
white = missing); GRADE (black = high, blue = intermediate, sky blue = low, and white = missing), BASAL.MARK. (black = high and white = low), ERBB2-
AMP (black = high and white = low). The BASAL.MARK. profile represents an average over validated basal markers in [27], whereas the ERBB2-AMP 
profile was calculated as an average over three genes in the ERBB2 amplicon (ERBB2, STARD3, GRB7). (b) Kaplan-Meier curves for time to distant 
metastasis (years) and for the five subclasses identified in panel (a). (c) Partitioning around medoids clustering over the seven-gene prognostic immune 
response module. Panel color codes: purple = cluster over-expressing module, yellow = cluster under-expressing module, black = poor outcome samples, 
gray = good outcome samples, green = relative under-expression, and red = relative over-expression. (d) Kaplan-Meier curves for time to distant 
metastasis for the two groups identified in panel (c). Hazard ratio, 95% confidence interval, and log-rank test P values are shown. ER, estrogen receptor; 
SSP, single sample predictor.
Table 2
Distribution of ER- samples among clusters, prognostic groups and intrinsic subtypes
Cluster n Outcome LI ER-
Good Poor High Low Luminal B Luminal A Normal Basal HER2
CC+/IR+ 3 9 2 5 1 4 720003 8 1
CC+ 3 7 1 8 1 7 350013 3 3
ECM+ 45 26 18 1 14 0 9 9 22 5
SR+ 3 6 1 6 2 0 2411023 2
IR+ 2 9 2 3 66604291 4
For the five clusters of Figure 2a, we give the number of samples per cluster (n) and their distributions over good/poor outcome, high/low 
lymphocytic infiltration (LI) score, and intrinsic subtypes as determined by the single sample predictor (SSP) classifier. Clusters were labeled by the 
main Gene Ontology of genes over-expressed in the group: CC+ (cell cycle), CC+/IR+ (cell cycle and immune response), ECM+ (extracellular matrix), 
SR+ (steroid hormone response), and IR+ (immune response). ER, estrogen receptor.
Table 3
Classification of ER+ intrinsic subtypes, medullary breast cancer, and BRCA1 tumors into ER- subclasses
ER+ MBC DBC BRCA1
Luminal B Luminal A Normal Basal HER2
n 9 73 3 7 3 21 94 22 24 41 8
n c l a s s i f i a b l e 3 71 1 3 1 91 71 62 03 31 6
CC+/IR+ 1 72 0 1 31 11 44 1 3
CC+ 2 0 2041332
ECM+ 07 1 1 6 00131
SR+ 0900002 0 0
IR+ 02 9 304230
Classification of ER+ intrinsic subtypes (527 samples from the integrated cohort NKI2 + EMC + NCH), 22 medullary breast cancers (MBCs) and 44 
ductal breast cancers (DBCs) from [38], and 18 BRCA1 mutants from [3] into ER- subclasses, using the nearest centroid criterion with Pearson 
correlation as distance metric. Only samples with Pearson correlation coefficients larger than 0.25 were deemed classifiable. ER, estrogen receptor.R157.8 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. http://genomebiology.com/2007/8/8/R157
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In contrast, application of the same method to ER+ breast
cancer yielded 29 genes (out of a possible 193) with P < 0.05
(Additional data file 2). In spite of there being only 29 genes
in this list, there were many with mitotic cell cycle functions,
notably UBE2C, MAD2L1, E2F1 and KIFC1, and GO enrich-
ment analysis confirmed that the cell cycle GO was the most
significantly enriched category followed by transcription
regulatory activity. This result for ER+ breast cancer confirms
findings reported elsewhere that poor prognosis in ER+ breast
cancer is related mainly to over-expression of genes in cell
cycle and cell proliferation pathways [3,5,7]. Notably, none of
the identified prognostic genes were related to immune
response functions.
Having identified a prognostic module of seven immune
response genes (henceforth called the IR module), we next
confirmed that clustering over this module resulted in clus-
ters significantly associated with clinical outcome. Specifi-
cally, the partitioning around medoids (pam) clustering
algorithm [29] with two centers predicted one cluster with 52
good outcome and 56 poor outcome patients, and another
cluster with 56 good outcome and only 19 poor outcome
events, which was highly significant under Fisher's exact test
(P = 0.0004; Figure 3c). Kaplan-Meier and Cox regression
analyses further confirmed that the group not over-express-
ing the seven-gene module (out of the seven genes the major-
ity [six] are not over-expressed) had a greater risk for distant
metastasis (HR 2.02, 95% CI 1.2 to 3.4; P = 0.009; Figure 3d).
Relation to STAT1 and IFN cluster
Next, we investigated the relation of the good prognosis sub-
group identified here with the novel IFN regulated cluster
identified recently [23]. As shown previously [23], the IFN
cluster, defined by over-expression of interferon regulated
Expression profiles of selected prognostic markers in ER- breast cancer Figure 4
Expression profiles of selected prognostic markers in ER- breast cancer. Expression profile (on a log2 scale) of selected prognostic markers (a) IGLC2 and 
(b) C1QA in the integrated cohort of 186 ER- tumours (NKI2 + EMC + NCH), and in the validation cohorts UPP and JRH-2. Good outcome samples are 
shown in green, and poor outcome samples in blue. Clusters were inferred using the variational Bayesian approach in NKI2 + EMC + NCH and the pam 
algorithm in the UPP and JRH-2 cohorts. Infered clusters are indicated by different shapes (triangles and diamonds). ER, estrogen receptor; pam, 
partitioning around medoids.
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genes, including the transcriptional regulator STAT1, was
most closely related to the basal subclass and had a prognos-
tic performance similar to that of luminal B samples when
compared with the luminal A and normal subtypes. Interest-
ingly, when compared with the basal and HER2+ subclasses,
the IFN group had better prognosis, although a formal com-
parison was not conducted by Hu and coworkers [23].
Among the 98 genes in the immune response gene cluster
(Figure 3a and Additional data file 1), we identified a total of
14 with interferon related functions, including STAT1, SP110,
NFKBI,  IFI44,  IFNGR1,  ISGF3G, and IRF7. Interestingly,
however, none of these genes showed association with prog-
nosis except SP110. Thus, although it appears that our sub-
class is related to the IFN class discovered by Hu and
coworkers [23], it is also distinct in that the associated prog-
nostic markers are not in the IFN cluster.
Immune response module predicts outcome 
independently of lymph node status
Because our IR gene cluster included STAT1 and interferon-
induced genes, and these genes have been shown to be asso-
ciated with lymph node (LN) metastasis [30], we considered
whether the subgroup of ER- samples over-expressing the 98-
gene IR cluster was significantly associated with LN status.
Because all patients in the ECM cohort were LN negative, this
analysis was only performed on the NKI2 and NCH cohorts
(109 ER- patients, of whom 42 had LN involvement). Using
pam clustering with two centers over these 98 genes and 109
samples, we found subgroups with similar proportions of LN
metastases (43 LN negative and 28 LN positive versus 24 LN
negative and 14 LN positive; Fisher's exact test P = 0.84).
Moreover, clustering only over the 14 genes involved in the
IFN subcluster still did not show a significantly nonrandom
distribution of LN metastases among the clusters (P = 0.23),
although in agreement with Huang and coworkers [30] the
cluster over-expressing the IFN genes had proportionally
more LN metastases. Similarly, the distribution of LN metas-
tases among the two clusters predicted by the IR module was
not significantly different from random (P = 0.48). While LN
status itself was a significant predictor of distant metastasis
both in univariate (HR 2.28, 95% CI 1.36 to 3.85; P = 0.002)
and multivariate (HR 2.16, 95% CI 1.28 to 3.64; P = 0.004)
Cox regression analysis (this result is for a multivariate model
including LN status and the IR module as predictors.), impor-
tantly, the IR module remained a prognostic predictor for
TTDM (HR 1.93, 95% CI 1.14 to 3.26; P = 0.015) in the multi-
variate model that included LN status (Table 4). This showed
that the IR module identified here adds independent prog-
nostic value over LN status in ER- breast cancer.
Immune response module predicts outcome 
independently of lymphocytic infiltration
The upregulation of immune response genes in good progno-
sis tumors could be explained by the fact that these tumors
elicit a stronger immune and inflammatory response, as
measured for example by a higher degree of lymphocytic
infiltration (LI). The association of high LI with good progno-
sis is well known [31-34], and although a few conflicting
results have also been reported [35-37], we thought it natural
to consider whether upregulation of the identified immune
response module conferred good prognosis independently of
LI. To this end, we scored the samples in the NCH cohort for
LI (see Materials and methods, below) and combined these
with the available LI score information from the NKI2 cohort,
yielding a total of 50 scored samples. We found that although
there were proportionally more tumors with high LI scores in
the group over-expressing the immune response genes (spe-
cifically there were 11 high LI and 9 low LI samples versus 8
high LI and 22 low LI in the under-expressed group; Fisher
test, P = 0.07), a multivariate Cox regression with TTDM as
the outcome variable and the seven-gene IR module and LI
score as predictors showed that the immune response module
was still a strong predictor of clinical outcome, independent
of LI (HR 2.05, 95% CI 0.71 to 5.97; P = 0.19; Table 4). (The P
value is only marginally below statistical significance, which
is most likely due to the relatively small sample size.)
Supporting this result further, we did not find in ER- tumors
any significant association between LI and clinical outcome
(Table 4).
Relation to medullary and BRCA1 ER- breast cancer
To further confirm the independent prognostic power of the
IR module from LI, we investigated the relationship of the
identified good prognosis tumors with medullary breast
cancers (MBCs), which are characterized by high LI scores
and relatively good prognosis [38]. Thus, we considered to
which ER- subclass the 22 MBC expression profiles from the
report by Bertucci and coworkers [38] were most similar
( T a b l e  3 ) .  ( F o r  c o m p l e t e n e s s  a n d  r e f e r e n c e ,  w e  a l s o  p e r -
formed the analysis for the 44 ductal breast cancers [DBCs],
also profiled by Bertucci and coworkers [38].) This showed
that of the 22 MBCs, 20 showed reasonably strong correlation
to one of the ER- subclass centroids, 14 of which (70%) were
most similar to the CC+/IR+ subtype, whereas only two (11%)
were most similar to the IR+ subtype. In contrast, for the 33
DBC which could be classified, only four (12%) and three (9%)
were most similar to the CC+/IR+ and IR+ subtypes. These
results mirror the distribution of LI scores across the five ER-
subclasses (Figure 3a and Table 2) and further confirms that
the best prognostic group (IR+) is not related to MBC,
whereas CC+/IR+ is.
A similar analysis was performed for BRCA1 mutant tumors.
Of the 16 BRCA1 mutants from the NKI2 cohort [3], which
were also deemed classifiable based on a 0.25 correlation
threshold, 13 (81%) had expression profiles most similar to
the CC+/IR+ subtype (Table 3). None showed similarity to the
IR+  subclass. Therefore, this suggests that ER-  BRCA1
mutants, in common with MBCs, are most similar to the CC+/
IR+ subclass identified here.R157.10 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. http://genomebiology.com/2007/8/8/R157
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External validation
Having identified a prognostic module related to immune
response, we next attempted to validate this finding using two
independent breast cancer cohorts [7,19]. Specifically, the
hypothesis to be tested was that over-expression of the iden-
tified prognostic markers is associated with good prognosis,
except for SPP1, for which good prognosis is hypothesized to
be associated with under-expression. Because of the relatively
small sample size of the two external cohorts, an algorithm
that attempts to learn the optimal number of clusters (as
implemented in PACK) is unlikely to capture structure
because of a large false negative rate [39]. Hence, in order to
define groups of over-expression and under-expression, we
applied the pam algorithm with two centers to each of the
seven genes in each of the two cohorts (Figure 4 and Addi-
tional data files 6 and 7). Because the small number of events,
six, in each of the two external cohorts implied a highly
discrete P value distribution, Fisher test P values would be too
conservative and poor approximations for type I errors [40].
To overcome this difficulty, we also considered the distribu-
tion of good and poor outcome samples over the combined
clusters of over-expression and under-expression (Table 5).
This showed that four of the seven genes (C1QA,  IGLC2,
TNFRSF17, and LY9) were also highly prognostic in these two
external cohorts, thus confirming the validity of our finding.
Moreover, as in the three original cohorts, over-expression of
these genes in the two external cohorts was associated with
good prognosis (Figure 4 and Additional data files 6 and 7).
For the other three genes (HLA-F, SPP1, and XCL2), P values
did not reach statistical significance (P about 0.2), yet their
expression profile trends were entirely consistent with those
found in the integrated cohort, thus confirming their role as
members of a robust prognostic module (Additional data files
6 and 7).
To confirm the robustness of our findings, we used the pam
algorithm to classify patients in the two external cohorts into
clusters over-expressing and under-expressing the IR module
(Figure 5a,b). Remarkably, the predicted 20-sample cluster
over-expressing the module was composed entirely of good
outcome patients, whereas the remaining 35-sample cluster
included 12 poor outcome events (Figure 5c), which was
highly significant under Fisher's exact test (P = 0.002; the HR
is singular because one cluster did not have any events).
The prognostic value of the IR module is specific to ER- 
tumours
To confirm that the good prognosis conferred by activation of
the IR module is specific to ER- breast cancer, we applied the
same pam clustering algorithm over the seven genes to the
integrated dataset of 527 ER+ breast tumors. This gave two
clusters with unequal distributions of good and poor outcome
samples (209 good and 99 poor for the cluster under-express-
ing the genes versus 163 good and 47 poor for the cluster over-
expressing the genes; P = 0.02). Although this suggested to us
that over-expression of this seven-gene module also con-
ferred better prognosis in ER+ samples, the association was
much weaker than for ER- samples. Univariate Cox regression
with TTDM as the outcome variable confirmed that under-
expression of this seven-gene module conferred a much
greater risk for distant metastasis in ER- tumors (HR 2.02,
95% CI 1.2 to 3.4; P = 0.009) than in ER+ tumors (HR 1.25,
95% CI 0.9 to 1.7; P = 0.16; Table 4). It is also noteworthy that,
in contrast to the ER- case, in the multivariate model setting
for ER+ tumors, a low LI score and LN involvement were
s t r o n g e r  p r e d i c t o r s  o f  T T D M  t h a n  t h e  s e v e n - g e n e  m o d u l e
(HR 1.65, 95% CI 0.4 to 7.1 for LI score and HR 1.48, 95% CI
0.7 to 3.2 for LN involvement, versus HR <1; Table 4). The
specificity of our prognostic module to ER- breast cancer was
Table 4
Univariate and Multivariate Cox-regression model
ER- (n = 186) ER+ (n = 527)
HR (95% CI) P HR (95% CI) P
LN 2.28 (1.36-3.85) 0.002 2.07 (1.47-2.90) <10-4
LI 1.06 (0.66-1.70) 0.9 1.50 (0.72-3.14) 0.58
IRM 2.02 (1.19-3.41) 0.009 1.25 (0.91-1.71) 0.19
LNa + IRM 2.16 (1.28-3.64) 0.004 2.10 (1.49-2.96) <10-4
LN + IRMa 1.93 (1.14-3.26) 0.015 1.29 (0.94-1.76) 0.11
LIa + IRM 0.86 (0.32-2.28) 0.76 1.75 (0.41-7.47) 0.45
LI + IRMa 2.05 (0.71-5.97) 0.19 0.57 (0.27-1.19) 0.13
LNa + LI + IRM 1.79 (0.70-4.62) 0.22 1.48 (0.68-3.19) 0.32
LN + LIa + IRM 0.84 (0.51-1.38) 0.72 1.65 (0.38-7.07) 0.5
LN + LI + IRMa 2.22 (0.76-6.50) 0.15 0.57 (0.27-1.20) 0.14
The table summarizes the hazard ratio (HR), 95% confidence interval (CI), and log-rank test P values of univariate Cox proportional hazards 
regression models, with lymph node status (LN = 1/0 for LN +/-), level of lymphocytic infiltration (LI = 1 for low infiltration score, and LI = 0 for high 
infiltration score) and the classification based on the seven-gene immune response related module (IRM; 2 = down-regulation of module, 1 = 
upregulation of module) as predictors. aCorresponding values in the multivariate Cox models including LN, LI, and IR module as predictors. The 
table compares the values for estrogen receptor (ER)- and ER+ breast cancer.http://genomebiology.com/2007/8/8/R157 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. R157.11
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2007, 8:R157
confirmed by application of PAC, which showed that, with the
exception of XCL2, none of the other six genes were individu-
ally prognostic.
In this context, it is worth noting once again the absence of
immune response related genes among the 29 PAC derived
prognostic genes in ER+ disease, which would suggest that a
good prognosis IR related subtype is absent in ER+ breast
cancer. To investigate this further we checked, by performing
Wilcoxon rank sum tests on the 5,007 genes, that the absence
of immune response GOs was not just an artefact of the small
number of genes picked out by PACK. In fact, GO analysis
(using GOTree Machine) of the top 500 genes obtained from
this rank sum test (all with q-values < 0.05) showed that cell
cycle and transcription regulator activity related GOs were
the only categories with highly significant P values (uncor-
rected P < 10-6), and that the only enriched immune response
related GO was that of humoral immune response, with 11
represented genes (including BLM,  FADD,  C3,  C7,  BCL2,
NFKB1, and the IR module member TNFRSF17), and which
was only marginally enriched (uncorrected P  = 0.005).
Although we verified that this humoral immune response
module was associated with prognosis in the integrated ER+
cohort independent of LN status and LI (HR 2.26, 95% CI
0.97 to 5.26; P = 0.06) we were unable to validate this prog-
nostic module in the external UPP and JRH-2 cohorts
(Additional data file 8). Moreover, the co-regulation patterns
for the genes in this module were less coherent than those for
the IR module in ER- breast cancer (Figure 5 and Additional
data file 8). Hence, independent of the methodology used, an
IR related prognostic module in ER+ breast cancer could not
be identified, which seems to suggest that a good prognosis
subtype related to IR is specific to ER- disease.
Discussion
A striking difference between ER+ and ER- disease is emerg-
ing at the level of mRNA expression. Although in ER+ disease
a significant number of genes have been found that correlate
with clinical outcome [5,10,18,22], in ER- disease no such
prognostic signatures have thus far been reported. Moreover,
although in ER+  tumors subtypes of different prognostic
risks, the luminal A and B subtypes, have been defined
[21,22], no such subdivisions have been noted for ER- breast
cancer. It is known that the two main subtypes of ER- breast
cancer (ER-/HER2+ and basals) have worse prognosis com-
pared with the luminal A subtype, but no outcome differences
between the ER-/HER2+  and basal subtypes have been
observed [15,21-23,26].
We believe that these differences between ER+ and ER- dis-
ease are related to the different histopathologic characteris-
Table 5
External validation of immune response prognostic module: distribution of poor and good outcome patients in over-and-under-
expressed subgroups
Gene UPP JRH-2 Combined
Poor Good P Poor Good P Poor Good P
IGLC2 High 0 12 0.04 0 7 0.09 0 19 0.003
Low 6 13 6 11 12 24
LY9 High 1 16 0.05 0 6 0.14 1 22 0.007
Low 5 9 6 12 11 21
TNFRSF17 High 1 16 0.05 0 10 0.02 1 26 0.001
L o w 5 96 81 1 1 7
C1QA High 0 12 0.04 0 9 0.04 0 21 0.001
Low 6 13 6 9 12 22
Pam clustering over IR module in external ER- cohorts Figure 5
Pam clustering over IR module in external ER- cohorts. Heatmap of gene 
expression of seven-gene IR-module in ER- samples of the (a) UPP and (b) 
JRH-2 cohorts. Shown are the clusters over-expressing (purple) and 
under-expressing (yellow) the IR module, as predicted by the pam 
algorithm. Good outcome samples are shown in gray, and poor outcome 
samples in black. Green indicates relative under-expression, and red 
indicates relative over-expression. (c) Kaplan-Meier survival curves over 
combined external cohorts (for UPP end-point was disease-specific 
survival, and for JRH-2 it was recurrence-free survival), with the number 
of events and samples in each of the two predicted groups. ER, estrogen 
receptor; pam, partitioning around medoids.
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tics of the tumors. The prognostic signatures derived for ER+
breast cancer are characterized by genes related to cell cycle
and cell proliferation pathways, and are also highly correlated
with the histologic grade of the tumors [7,22]. It is not a
coincidence that most luminal B tumours are of high grade,
whereas the great majority of luminal A tumours are of low
grade [7,22]. It appears that there may be a whole plethora of
diverse oncogenic pathways that drive the over-activation of
cell cycle and cell growth pathways in poor prognosis tumors.
This would explain the larger number of prognostic genes
found in ER+ disease (the great majority of which are related
to cell cycle ontologies) as well as the stronger prognostic sig-
nals (relatively large differences in log2 expression between
poor and good prognosis tumours), an effect that is probably
driven by oncogenic amplifications. This interpretation
would also fit in well with our finding that most bimodal pro-
files in ER+  breast cancer have positive kurtosis values,
because this could be a reflection of a more diverse range of
small amplifier subgroups in ER+ breast cancer.
In contrast, most ER- tumours are of high grade, which would
explain why any differences in clinical outcome within ER-
disease are not related to differential activation of cell cycle
pathways. Instead, the work presented here shows that differ-
ences in clinical outcome within ER-  disease are mainly
related to differentially expressed genes in the complement
and immune response pathways, and that the association
with prognosis can be independent of lymphocytic infiltration
(LI) and LN status. In fact, for ER- tumors we observed that
even though there were proportionally more high LI samples
in the group over-expressing the IR module, these did not
necessarily have better prognosis. The fact that LI could not
explain the observed association of the IR module with out-
come was supported further by our finding that medullary
breast cancers, which are characterized by high LI scores, had
expression profiles most similar to the CC+/IR+  subtype
rather than the IR+ subtype, which had the best prognosis
overall. The better prognosis of the CC+/IR+ subtype relative
to CC+  and SR+  ER-  breast cancer is therefore entirely
consistent with the CC+/IR+ subclass being medullary breast
cancers (MBCs), as MBC is known to have marginally better
prognosis than other basal tumors [38]. On the other hand,
the IR+ subclass, which had the best prognosis among the five
ER- subclasses, was only marginally associated with high LI
and was unrelated to MBC. Also consistent with these obser-
vations, it is important to note again the distinction between
the identified seven-gene prognostic IR module and the 98-
gene IR cluster that was derived from unsupervised hierarchi-
cal clustering. Clearly, we found a strong statistical associa-
tion between high LI and over-expression of the 98-gene IR
cluster. Specifically, there were 13 high LI and eight low LI
samples in the combined IR+ and CC+/IR+ clusters relative to
six high LI and 23 low LI samples in the rest of the cohort
(Fisher test P = 0.007). In contrast, the association between
high LI and over-expression of the IR module was much
weaker (P  = 0.07). Again, this suggests that a significant
number of genes in the 98-gene IR cluster show expression
variability that is not explained by LI. This is confirmed fur-
ther by two recent studies that profiled breast cancer cell lines
[27,38], which showed that a considerable number of
immune response related genes do exhibit significant
variable expression across the basal cell subtype. Moreover,
we found that two (SPP1 and HLA-F) of the three IR module
genes that we could map to good quality probes in [27,38]
showed twofold changes across the eight basal cell lines.
Thus, these findings together suggest that a significant pro-
portion of the expression of the IR module genes in the good
prognosis tumors is tumor-intrinsic in origin. That tumor-
intrinsic expression of IR genes can have an impact on prog-
nosis of breast cancer patients is plausible in view of recent
studies that show, for example, how amplification of kinase
oncogenes can activate the nuclear factor-κB pathway, and
hence immune response pathways, in both breast cancer cell
lines and patient derived breast tumors [41]. Similarly,
another recent study [42] used breast cancer cell lines to show
how BRCA1/IFN-γ  pathways may regulate target genes
involved in innate immune response, providing another pos-
sible mechanism for tumor intrinsic IR gene expression
variability.
In spite of identifying only a relatively small module of prog-
nostic genes, we were nevertheless able to validate their prog-
nostic potential in two external cohorts. It is likely that an
integrative analysis similar to the one used here but applied to
multiple cohorts that were all profiled on exactly the same
genome-wide platform would allow further expansion of this
module to include other members of the complement and
immune response pathways. Interestingly, from the seven
prognostic markers that composed the IR module, two have
already been associated with clinical outcome in breast can-
cer. Specifically, C1QA, which is a gene involved in the classi-
cal complement pathway, was recently shown to harbor a
single nucleotide polymorphism that correlated with distant
metastasis in breast cancer [43]. Two recent studies also
implicated  SPP1  (osteopontin) in metastatic breast cancer
[44,45].
It is important also to note that the robustness of the identi-
fied prognostic markers is a consequence of the PACK meth-
odology. Despite being a conservative procedure that filters
out many true positives, PACK allows, by efficient removal of
false positives, a more reliable identification of prognostic
markers. We tested this further by applying two popular sta-
tistical tools, singular value decomposition (SVD) [46] and
the shrunken centroids classifier (PAMR) [47], to the inte-
grated ER- dataset to determine whether we could derive a
similar if not identical prognostic IR module. Using SVD we
found that none of the inferred SVD components showed a
correlation with prognosis (Wilcoxon rank sum test P > 0.05),
whereas at a FDR threshold of 0.3 PAMR yielded 21 prognos-
tic genes, of which only two (the IR module memberhttp://genomebiology.com/2007/8/8/R157 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. R157.13
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TNFRSF17 and KLRD1) had immune response related func-
tions. Thus, in agreement with findings presented previously
[17], this reinforces the advantage of PACK over other pattern
recognition tools and supervised methods that do not use
pattern recognition steps, such as for example those based on
t-tests.
The absence of a prognostic IR module in ER+ breast cancer
is intriguing. The seven-gene IR module was only marginally
associated with prognosis in ER+ disease, and importantly
this association was not independent of LI or LN status.
Repeating the same unsupervised analysis (PAK) and semi-
supervised analysis (PACK) in ER+ breast cancer also did not
find a prognostic immune response module. By using a tradi-
tional supervised method, a prognostic IR module was iden-
tifiable but failed to validate in the two external cohorts. Thus,
to determine fully whether such a robust prognostic IR mod-
ule exists for ER+ breast cancer, it may be necessary to con-
duct larger integrative studies that use the same microarray
platform so that the analysis can be performed over a larger
set of common genes.
Besides identifying a module of genes that is prognostic in
over 240 ER- breast tumors, PACK also provided us with a
novel subclassification of ER- breast cancer. Specifically, clus-
tering over PACK selected genes identified five different sub-
types (CC+, CC+/IR+, IR+, ECM+, and SR+) characterized by
the over-expression patterns of four distinct gene clusters,
each enriched for IR, ECM, CC, and SR genes, respectively.
Moreover, we related these subtypes to the gene expression
based intrinsic subclasses. This showed that the basal sub-
group was a heterogeneous group with at least four distinct
subtypes (CC+, CC+/IR+, ECM+, and IR+), whereas the ER-/
HER2+ subgroup showed strong overlap with the SR+ and IR+
subtypes.
Conclusion
While in ER+ breast cancer prognostic markers are associated
mainly with cell cycle pathways, in ER- disease prognostic
markers are associated with immune response pathways. In
particular, we have identified a subclass of ER- tumors that
over-express immune response genes and that has a good
prognosis compared with the rest of ER- breast tumors, inde-
pendently of LN status or LI. Furthermore, we have identified
an associated module of complement and immune response
genes that define prognostic markers valid in over 240 ER-
samples.
Materials and methods
Datasets and gene annotation
The microarray breast cancer datasets considered in this
work are described elsewhere [5,7,9,18,19]. For these cohorts
we used the normalized data, which are available in the public
domain (see [5,7,9,18,19]). The retrieved datasets were fur-
ther normalized, if necessary, by transforming them onto a
common log2 scale and shifting the median of each array to
zero. We also created an automated computational pipeline
(Perl scripts on a Linux platform) to crosslink the annotation
provided for each dataset with UniGene. For some datasets,
the linkage relied on Ensembl [48] external database identifi-
ers. Thus each probe was associated with a universal gene
name. This procedure generated a nonredundant set of gene
identifiers for the subsequent integrative analysis.
PACK: profile analysis using clustering and kurtosis
The hypothesis underlying PACK [17] is that genes that are
true biologic or clinical markers have expression profiles that
are generated by a mixture of two or more underlying distri-
butions, whereas spurious features are more likely to have
profiles generated by a single distribution. The biologic valid-
ity of this assumption was proved through a FDR analysis
[17].
PACK can be viewed as a semi-supervised algorithm, consist-
ing of two main steps: a feature selection criterion and a
supervised step, in which the selected features are correlated
to a phenotype (Figure 2). It is important to note that PACK is
a flexible modular algorithm in that the feature selection step
can be applied on its own. In this case, there are two possible
versions of the algorithm: PAC and PAK. The precise way in
which these two algorithms are used in PACK will depend on
the purpose of the exercise. Below, we describe the PACK
strategy implemented in this paper, which is slightly different
from that applied previously [17].
Feature selection with PAK: using negative kurtosis to 
find genes defining major subclasses
Kurtosis is related to the fourth central moment and can con-
veniently be defined as follows [49]:
where X is any random variable and E denotes the expecta-
tion. For a gaussian  , so that
K(X) = 0. Most nongaussian distributions necessarily have
either K > 0, in which case they are called supergaussian or
leptokurtic, or K < 0, in which case they are called subgaus-
sian or platykurtic. Specifically, a mixture of two approxi-
mately equal mass gaussians must have negative kurtosis
because the two modes on either side of the center of mass
effectively flatten out the distribution. To see this, consider a
gene whose expression profile is described by a mixture of
two gaussians. Then, the kurtosis, K, is a function of two
parameters (we assume for simplicity that the gaussians are
of equal variance σ2, although this assumption is not needed
for the result below); the effect size of the gene, as defined by
the effective separation e between the two gaussians (e = μ/σ,
where μ is the separation), and the ratio of cluster weights (π1,
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π2), that is R = π1/(1 - π1). Specifically, a short computation
reveals that
where a and b are the quadratic roots 2 ± √3. Thus, for e ≠ 0,
the kurtosis is negative if and only if (2 - √3) < R < (2 + √3).
This in turn requires the smallest cluster weight, πmin, to be in
the range (approximately) of 0.22 <πmin < 0.5. It follows that
for the case of approximately equal weights, where R ≅ 1 (πmin
≅ 0.5), the kurtosis is always negative and in the limit of large
cluster separations (when e >> 1) the kurtosis decreases
monotonically, asymptotically approaching the lower bound -
2. Thus, kurtosis provides a useful measure for ranking genes
based on how platykurtic their profiles are.
Given a gene's expression profile x = (x1, ..., xn), an unbiased
estimate for the kurtosis [50] is as follows:
where   and  σ are the mean and standard deviation esti-
mates of the profile. A standard error estimate of K was
obtained by performing 10,000 random simulations, with n =
186 (number of ER- samples), which showed that the stand-
ard error estimate, 0.36, was essentially identical to the theo-
retical estimate, √(24/n) [50].
Two notes with the feature selection step are in order. First,
the kurtosis threshold used to select features depends on how
large the smallest subgroup must be. Generally, given the
effective separation values that are typical for differential
gene expression, we find that a zero kurtosis threshold (as
used in this report) generally picks out subgroups within the
individual gene expression profiles that are at least as large as
30% of the total sample size [17]. Second, in principle, genes
defining major subclasses could be found using a clustering
step to infer two clusters (PAC) and setting a lower bound
threshold (for instance, 30%) on the size of the smallest clus-
ter. However, this approach is computationally more expen-
sive, because PAC attempts to estimate the optimal number of
clusters in the profile. However, this model selection step is a
necessary one to ensure that profiles for which there is no
objective evidence of bimodality are excluded (see below).
PAC: identification of robust prognostic markers
Having selected the genes defining the largest subclasses, we
next apply PAC to each of these genes to remove those for
which there is no evidence of bimodality (gaussian profiles
that spuriously have negative kurtosis values). Specifically,
given a gene's expression profile x = (x1, ..., xn), we model this
as a random sample of a univariate random variable X, whose
density function is possibly a mixture of Gaussians:
Where πk are the weights of the components, (μk, σk) are the
mean and standard deviation of the univariate gaussian k,
and θ denotes the set of all parameters. In the above, CM
denotes the maximum number of clusters that can be
inferred, which in our application we set to 2. The optimal
number of clusters, C, can be inferred using one of various
approaches. One possibility is to use the EM algorithm to
learn the parameters for the two different models C = 1 and C
= 2, and perform model selection using the Bayesian Infor-
mation Criterion (BIC) score [51,52]. Alternatively, the opti-
mal number of clusters, C, can be inferred using a lower
bound on the model evidence, as provided by a variational
Bayesian (VB) approach [39,53,54]. The results we report
here were obtained using the VB algorithm for model selec-
tion. Thus, genes for which C = 1 were excluded from further
analysis. Finally, association with the phenotype (here prog-
nosis) was determined using Fisher's exact test to test
whether poor outcome events were unevenly distributed
across the two clusters.
Software packages used
All analyses were performed using the R statistical program-
ming language [55]. The following add-on packages were
used: vabayelMix for the PACK implementation, survival for
the Cox regression models, qvalue for FDR estimation, and
cluster for the partitioning around medoids (pam) clustering
algorithm.
The SSP classifier
The classification of the samples in the NKI2, EMC, and NCH
cohorts into the intrinsic subtypes was performed using the
single sample predictor (SSP) [23] and was done for each
cohort separately because this guaranteed a larger number of
overlapping genes. In the SSP, samples were assigned the
intrinsic subtype for which the corresponding Spearman rank
correlation between the sample and SSP centroid was maxi-
mal [23].
The ER- subclass centroids
From the hierarchical clustering with Pearson correlation
metric and complete linkage diagram (Figure 3a) we con-
structed mean centroids for each of the five subclasses. Clas-
sification of external samples to these centroids was
performed using the nearest centroid criterion. Because these
centroids were defined over ER- samples only, external sam-
ples (which may not be ER-) may not show strong correlation
to any of these centroids. We thus validated, through 10,000
Monte Carlo (MC) randomisations, that samples with a max-
imal pearson coefficient larger than 0.25 were significantly
correlated with the corresponding centroid (P  < 0.0001).
Samples with maximal correlation coefficients smaller than
0.25 were deemed to be unclassifiable.
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Expression based basal and HER2+ markers
The basal marker used in Figure 3 was derived by first map-
ping ten validated basal markers (CRYAB, ANXA8, LAMC2,
LAMB3, ITGA6, KRT17, KRT15, KRT13, KRT6B, and KRT5)
[27] onto the integrated data set of 5,007 genes. For each of
these markers samples were ranked in order of decreasing
expression or 'basalness'. For each sample in the integrated
cohort an average rank was then computed over the ten basal
markers. The average ranks were then rescaled onto the unit
interval (0,1), with '1' indicating highest expression for basal
markers. The marker for the ERBB2 subtype was obtained in
an analogous manner using three genes in the ERBB2 ampli-
con (ERBB2, GRB7, and STARD3).
Lymphocyte infiltration scores
For the samples from our NCH cohort [9] we used the follow-
ing scoring method. Lymphocytic infiltration (LI) was
assessed in whole tumour sections from frozen sections
stained with hematoxylin and eosin. The intensity of lym-
phocytic infiltrate was first graded semi-quantitatively as
minimal or mild (1), moderate (2), and marked (3). The LI
scores were then dichotomized (we considered mild and
moderate as low LI and marked as high LI) to make them
comparable with the binary LI scores used by van 't Veer and
coworkers [3].
Additional data files
The following additional data are available with the online
version of this manuscript. Additional data file 1 is a table
showing the 813 genes with negative kurtosis expression
profiles over 186 ER- tumors, together with the predicted
number of clusters and Fisher's test P value with outcome as
binary phenotype. Additional data file 2 is a table showing the
193 genes with negative kurtosis expression profiles over 527
ER+ samples, together with the predicted number of clusters
and Fisher's test P value with outcome as binary phenotype.
Additional data file 3 is a figure showing hierarchical cluster-
ing over 186 ER- breast cancers (gene annotated version).
Additional data file 4 is a figure showing the distribution of
basal and ERBB2 markers among ER- subtypes. Additional
data file 5 is a table showing the centroids of gene expression
for each of the five identified ER- subtypes. Additional data
file 6 is a figure showing expression profiles of immune
response module genes in ER- samples of the external UPP
cohort. Additional data file 7 is a figure showing expression
profiles of immune response module genes in ER- samples of
the external JRH-2 cohort. Additional data file 8 is a figure
showing the clustering of ER+ samples over the humoral
immune response gene module in the two external UPP and
JRH-2 cohorts.
Additional data file 1 Genes with negative kurtosis expression profiles in ER- breast  cancer Columns label the gene, the negative kurtosis of its expression pro- file over 186 ER- samples, the number of clusters predicted by PAC  and Fisher's test P value testing for an association between out- come and the two clusters. Click here for file Additional data file 2 Genes with negative kurtosis expression profiles in ER+ breast  cancer Columns label the gene, the negative kurtosis of its expression pro- file over 527 ER+ samples, the number of clusters predicted by PAC  and Fisher's test P value testing for an association between out- come and the two clusters. Click here for file Additional data file 3 Hierarchical clustering over 186 ER- breast cancers: gene anno- tated version Hierarchical clustering over 186 ER- breast cancers and 813 nega- tive kurtosis profile genes selected using the PAK algorithm, as  explained in the text. Five main clusters were identified and char- acterized in terms of over-expression of genes related to cell cycle  (CC), immune response (IR), extracellular matrix (ECM), and ster- oid hormone response (SR) functions. Red denotes relative over- expression and green relative under-expression. Click here for file Additional data file 4 Distribution of basal and ERBB2 markers among ER- subtypes (A) Hierarchical clustering dendrogram with the different ER- sub- types as defined by the clustering in Figure 2a. (B) The distribution  of lymphocytic infiltration scores (LI) and histologic grade. Color  codes: black = high LI and high grade; gray = low LI; blue = inter- mediate grade; and sky blue = low grade. (C) Expression profiles of  validated basal markers from [27] across ER- subtypes. (D)  Expression profiles of genes in the ERBB2 amplicon. Color codes:  green = relative under-expression; red = relative over-expression. Click here for file Additional data file 5 Gene expression centroids for ER- subclasses Table gives the gene expression centroids over the five identified  ER- subclasses. Centroids were defined over the 813 genes with  negative kurtosis expression profiles. Click here for file Additional data file 6 Expression profiles of immune response module genes in ER- sam- ples of external UPP cohort Expression profiles (on a log2 scale) of immune response module  genes in the validation ER- cohort UPP. Black indicates good out- come samples and red poor outcome samples. Clusters were  inferred using the pam algorithm. Inferred clusters are indicated by  different shapes (triangles and diamonds). Click here for file Additional data file 7 Expression profiles of immune response module genes in ER- sam- ples of external JRH-2 cohort Expression profiles (on a log2 scale) of immune response module  genes in the validation ER- cohort UPP. Black indicates good out- come samples and red poor outcome samples. Clusters were  inferred using the pam algorithm. Inferred clusters are indicated by  different shapes (triangles and diamonds). Click here for file Additional data file 8 Humoral immune response module in external ER+ cohorts Heatmap of gene expression of the 11-gene humoral IR module in  the ER+ samples of the (A) UPP and (B) JRH-2 cohorts. Shown are  the clusters over-expressing (purple) and underexpressing (yellow)  the humoral IR module as predicted by the pam algorithm. Good  outcome samples are presented in gray and poor outcome samples  in black. Green indicates relative under-expression, and red rela- tive over-expression. (C) Kaplan-Meier survival curves over com- bined external cohorts (for UPP the end-point was disease-specific  survival, and for JRH-2 it was recurrence-free survival), with the  number of events and samples in each of the two predicted groups. Click here for file
Acknowledgements
This research was supported by grants from Cancer Research UK. We
thank Ali Naderi for useful discussions.
References
1. Brenton JD, Carey LA, Ahmed AA, Caldas C: Molecular classifica-
tion and molecular forecasting of breast cancer: ready for
clinical application?  J Clin Oncol 2005, 23:7350-7360.
2. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO: Breast
carcinoma with basal differentiation: a proposal for pathol-
ogy definition based on basal cytokeratin expression.  Histopa-
thology 2007, 50:434-438.
3. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M,
Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene
expression profiling predicts clinical outcome of breast
cancer.  Nature 2002, 415:530-536.
4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker
MG, Watson D, Park T, et al.: A multigene assay to predict
recurrence of tamoxifen-treated, node-negative breast
cancer.  N Engl J Med 2004, 351:2817-2826.
5. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov
D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expres-
sion profiles to predict distant metastasis of lymph-node-
negative primary breast cancer.  Lancet 2005, 365:671-679.
6. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Hol-
mberg L, Huang F, Klaar S, et al.: Gene expression profiling spares
early breast cancer patients from adjuvant therapy: derived
and validated in two population-based cohorts.  Breast Cancer
Res 2005, 7:R953-R964.
7. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H,
Farmer P, Praz V, Haibe-Kains B, et al.: Gene expression profiling
in breast cancer: understanding the molecular basis of histo-
logic grade to improve prognosis.  J Natl Cancer Inst 2006,
98:262-272.
8. Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A,
Cufer T, Sieuwerts AM, Talantov D, Span PN, et al.: Multicenter val-
idation of a gene expression-based prognostic signature in
lymph node-negative primary breast cancer.  J Clin Oncol 2006,
24:1665-1671.
9. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green
AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, et al.: A
gene-expression signature to predict survival in breast can-
cer across independent data sets.  Oncogene 2007,
26:1507-1516.
10. Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO,
Aparicio S, Brenton JD, Caldas C: A consensus prognostic gene
expression classifier for ER positive breast cancer.  Genome
Biol 2006, 7:R101.
11. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O,
Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, et al.: Expres-
sion of cytokeratins 17 and 5 identifies a group of breast car-
cinomas with poor clinical outcome.  Am J Pathol 2002,
161:1991-1996.
12. Malzahn K, Mitze M, Thoenes M, Moll R: Biological and prognostic
significance of stratified epithelial cytokeratins in infiltrating
ductal breast carcinomas.  Virchows Arch 1998, 433:119-129.
13. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF,
Blamey RW, Macmillan D, Ellis IO: Basal phenotype identifies a
poor prognostic subgroup of breast cancer of clinical
importance.  Eur J Cancer 2006, 42:3149-3156.
14. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO:
Prognostic markers in triple-negative breast cancer.  Cancer
2007, 109:25-32.
15. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl
PO, Lundin M, Krogh M, Kataja P, Borg A, Ferno M, et al.: Basal-like
phenotype is not associated with patient survival in estro-
gen-receptor-negative breast cancers.  Breast Cancer Res 2007,
9:R16.
16. Eden P, Ritz C, Rose C, Ferno M, Peterson C: 'Good Old' clinical
markers have similar power in breast cancer prognosis as
microarray gene expression profilers.  Eur J Cancer 2004,
40:1837-1841.
17. Teschendorff AE, Naderi A, Barbosa-Morais NL, Caldas C: PACK:
Profile Analysis using Clustering and Kurtosis to find molec-
ular classifiers in cancer.  Bioinformatics 2006, 22:2269-2275.
18. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al.:  A gene-
expression signature as a predictor of survival in breast
cancer.  N Engl J Med 2002, 347:1999-2009.
19. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan
Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53R157.16 Genome Biology 2007,     Volume 8, Issue 8, Article R157       Teschendorff et al. http://genomebiology.com/2007/8/8/R157
Genome Biology 2007, 8:R157
status in human breast cancer predicts mutation status,
transcriptional effects, and patient survival.  Proc Natl Acad Sci
USA 2005, 102:13550-13555.
20. Storey JD, Tibshirani R: Statistical significance for genomewide
studies.  Proc Natl Acad Sci USA 2003, 100:9440-9445.
21. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of
breast tumor subtypes in independent gene expression data
sets.  Proc Natl Acad Sci USA 2003, 100:8418-8423.
22. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Mar-
tiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and
prognosis based on gene expression profiles from a popula-
tion-based study.  Proc Natl Acad Sci USA 2003, 100:10393-10398.
23. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA,
Reynolds E, Dressler L, et al.: The molecular portraits of breast
tumors are conserved across microarray platforms.  BMC
Genomics 2006, 7:96.
24. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Lar-
simont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, et al.:
Identification of molecular apocrine breast tumours by
microarray analysis.  Oncogene 2005, 24:4660-4671.
25. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL:
An estrogen receptor-negative breast cancer subset charac-
terized by a hormonally regulated transcriptional program
and response to androgen.  Oncogene 2006, 25:3994-4008.
26. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pol-
lack JR, Ross DT, Johnsen H, Akslen LA, et al.: Molecular portraits
of human breast tumours.  Nature 2000, 406:747-752.
27. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cer-
vera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F: Gene
expression profiling of breast cell lines identifies potential
new basal markers.  Oncogene 2006, 25:2273-2284.
28. Zhang B, Schmoyer D, Kirov S, Snoddy J: GOTree Machine
(GOTM): a web-based platform for interpreting sets of inter-
esting genes using Gene Ontology hierarchies.  BMC
Bioinformatics 2004, 5:1-8.
29. Kaufman L, Rousseeuw PJ: Finding Groups in Data: An Introduction to
Cluster Analysis New York: Wiley; 1990. 
30. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild
A, Iversen ES, Liao M, Chen CM, et al.: Gene expression predic-
tors of breast cancer outcomes.  Lancet 2003, 361:1590-1596.
31. Lee AH, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR: Dif-
ferent patterns of inflammation and prognosis in invasive
carcinoma of the breast.  Histopathology 2006, 48:692-701.
32. Marques LA, Franco EL, Torloni H, Brentani MM, da Silva-Neto JB,
Brentani RR: Independent prognostic value of laminin
receptor expression in breast cancer survival.  Cancer Res 1990,
50:1479-1483.
33. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S,
Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age
to pathologic features of the tumor and prognosis for
patients with stage I or II breast cancer.  J Clin Oncol 1994,
12:888-894.
34. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R,
Della Porta G, Menard S, Pierotti MA, Testori A: Prognostic signif-
icance of HER-2/neu expression in breast cancer and its rela-
tionship to other prognostic factors.  Int J Cancer 1991, 49:44-49.
35. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E,
Syrjanen K: Lymphocyte infiltrates as a prognostic variable in
female breast cancer.  Eur J Cancer 1992, 28A:859-864.
36. Holmberg L, Adami HO, Lindgren A, Ekbom A, Sandstrom A, Berg-
strom R: Prognostic significance of the Ackerman classifica-
tion and other histopathological characteristics in breast
cancer. An analysis of 1,349 consecutive cases with complete
follow-up over seven years.  APMIS 1988, 96:979-990.
37. Carlomagno C, Perrone F, Lauria R, de Laurentiis M, Gallo C, Mora-
bito A, Pettinato G, Panico L, Bellelli T, Apicella A, et al.: Prognostic
significance of necrosis, elastosis, fibrosis and inflammatory
cell reaction in operable breast cancer.  Oncology 1995,
52:272-277.
38. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E,
Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, et al.:
Gene expression profiling shows medullary breast cancer is
a subgroup of basal breast cancers.  Cancer Res 2006,
66:4636-4644.
39. Teschendorff AE, Wang Y, Barbosa-Morais NL, Brenton JD, Caldas C:
A variational Bayesian mixture modelling framework for
cluster analysis of gene-expression data.  Bioinformatics 2005,
21:3025-3033.
40. Agresti A: Categorical Data Analysis. Wiley Series in Probability and
Statistics New York: Wiley; 2002. 
41. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK,
Garraway LA, Weremowicz S, Richardson AL, et al.: Integrative
genomic approaches identify IKBKE as a breast cancer
oncogene.  Cell 2007, 129:1065-1079.
42. Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP,
Mullan PB: BRCA1 regulates IFN-gamma signaling through a
mechanism involving the type I IFNs.  Mol Cancer Res 2007,
5:261-270.
43. Racila E, Racila DM, Ritchie JM, Taylor C, Dahle C, Weiner GJ: The
pattern of clinical breast cancer metastasis correlates with a
single nucleotide polymorphism in the C1qA component of
complement.  Immunogenetics 2006, 58:1-8.
44. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ,
Holliday RL, Girvan DP, Scott LA, Postenka CO, et al.: Role of the
integrin-binding protein osteopontin in lymphatic metastasis
of breast cancer.  Am J Pathol 2006, 169:233-246.
45. de Silva Rudland S, Martin L, Roshanlall C, Winstanley J, Leinster S,
Platt-Higgins A, Carroll J, West C, Barraclough R, Rudland P: Asso-
ciation of S100A4 and osteopontin with specific prognostic
factors and survival of patients with minimally invasive
breast cancer.  Clin Cancer Res 2006, 12:1192-1200.
46. Alter O, Brown PO, Botstein D: Generalized singular value
decomposition for comparative analysis of genome-scale
expression data sets of two different organisms.  Proc Natl Acad
Sci USA 2003, 100:3351-3356.
47. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple
cancer types by shrunken centroids of gene expression.  Proc
Natl Acad Sci USA 2002, 99:6567-6572.
48. Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T,
Cuff J, Curwen V, Down T, et al.: The Ensembl genome database
project.  Nucleic Acids Res 2002, 30:38-41.
49. Balanda KP, MacGillivray HL: Kurtosis: a critical review.  Am Stat
1988, 42:111-119.
50. Snedecor GW, Cochran WG: Statistical Methods 6th edition. Ames,
IA: Iowa State University Press; 1967. 
51. Schwarz G: Estimating the dimension of a model.  Annls Stat
1978, 6:461-464.
52. Yeung KY, Fraley C, Murua A, Raftery AE, Ruzzo WL: Model-based
clustering and data transformations for gene expression
data.  Bioinformatics 2001, 17:977-987.
53. Attias H: Inferring parameters and structure of latent variable
models by variational bayes.  In Proceedings of the 15th Conference
on Uncertainty in Artificial Intelligence; 30-31 July 1999; Stockholm,
Sweden San Francisco, CA: Morgan Kaufmann; 1999:21-30. 
54. MacKay DJ: Developments in probabilistic modelling with
neural networks-ensemble learning.  In Neural Networks: Artificial
Intelligence and Industrial Applications. Proceedings of the 3rd Annual Sym-
posium on Neural Networks: 14-15 September 1995; Nijmengen, The
Netherlands Berlin: Springer; 1995:191-198. 
55. R Development Core Team: R: a language and environment for statistical
computing 2003 [http://www.R-project.org]. Vienna, Austria: R Foun-
dation for Statistical Computing